Itolizumab News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Itolizumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Itolizumab Today - Breaking & Trending Today
Remdesivir supply woes to ease in three weeks, says Biocon chief Top Searches Remdesivir supply woes to ease in three weeks, says Biocon chief Avik Das / TNN / May 3, 2021, 09:00 IST FacebookTwitterLinkedinEMail BENGALURU: Biocon executive chairperson Kiran Mazumdar-Shaw has said the country should be able to meet the huge demand for Remdesivir injections by the third week of May, and for Itolizumab and Tocilizumab drugs by the beginning of June. Biocon is a major manufacturer of these drugs beind used for treatment of Covid, with varied instructions. Remdesivir is to be administered only after a medical prescription and only on severely infected patients. The other two are used for the treatment of cytokine storm caused by the coronavirus. However, only Tocilizumab is part of the health ministry’s clinical management guidelines. ....
Being inhuman . Parasites abound in the time of a pandemic; beware of paying money online for medicines, oxygen or for ‘reserving’ beds Looks like the cyber crooks are not passing up on an opportunity to make money from the misfortune of the covid affected. It has come to the notice of the cybercrime authorities that cyber crooks are stealing the identity of health care centres, impersonating them and acting as dealers for drugs critical for covid treatment. Patient attendees trawling the internet for drugs like Tocilizumab and Itolizumab vials are falling prey to these crooks. They’re not only losing money but losing precious time in waiting for the drugs to be delivered which never happens, and in addition to this, they are seeing their loved one’s health failing. ....
The company does not look at Covid-19 related drugs as a business opportunity; it expects higher growth this fiscal year on the back of new biosimilar launches in both emerging and developed markets, Arun Chandavarkar, managing director of Biocon Biologics, told ET in an interview. ....
Read more about Biocon gains after Q4 PAT rises 105% YoY on Business Standard. Biocon rose 1.32% to Rs 396.10 after the company reported 105% jump in consolidated net profit to Rs 254 crore in Q4 FY21 from Rs 123 crore in Q4 FY20. ....